表紙
市場調查報告書

肺炎治療藥的全球市場:2017年∼2021年

Global Pneumonia Therapeutics Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 583019
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
肺炎治療藥的全球市場:2017年∼2021年 Global Pneumonia Therapeutics Market 2017-2021
出版日期: 2017年11月22日內容資訊: 英文 87 Pages
簡介

關於肺炎治療藥

肺炎是一種呼吸系統疾病,其特徵是由細菌或病毒感染引起的肺內氣囊炎症。肺炎治療市場包括用於治療肺炎以及氧療的藥物和疫苗。全球肺炎療法市場是全球呼吸障礙藥物市場的重要組成的一部分。肺炎的治療涉及三大類,即疫苗,藥物和氧療。當患者呼吸困難時,氧氣療法經常用作其他療法的補充。

Technavio的分析師預測,從2017年到2021年期間全球肺炎治療藥市場將以6.66%的年複合成長率成長。

本報告提供全球肺炎治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 市場概要

第5章 疾病概要

第6章 市場生態系統

  • 市場區隔分析

第7章 市場規模

  • 市場規模及預測

第8章 開發中產品分析

第9章 波特的五力分析

第10章 市場區隔:各產品類型

  • 市場區隔:各產品類型
  • 比較:各產品類型
  • 全球肺炎疫苗市場
  • 全球肺炎的抗感染藥市場
  • 全球肺炎氧氣療法市場
  • 市場機會:各產品類型

第11章 市場區隔:肺炎的各類型

  • CAP(社區型肺炎)
  • HCAP (醫療照護相關肺炎)

第12章 地區情形

  • 地理市場區隔
  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 市場機會

第13章 決策架構

第14章 成長要素與課題

  • 市場成長要素
  • 市場課題

第15章 市場趨勢

  • 強力的開發平台
  • 為了治療肺炎的全球配合措施的增加
  • 呼吸系統感染病例的增加

第16章 供應商情形

第17章 供應商分析

  • 供應商概要
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • Pfizer

第18章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR15799

About Pneumonia Therapeutics

Pneumonia is a respiratory disease characterized by inflammation of air sacs in lungs due to bacterial or viral infection. Pneumonia therapeutics market encompasses drugs and vaccines used for the treatment of pneumonia along with oxygen therapy. The global pneumonia therapeutics market is an important part of the global respiratory disorder drugs market. The treatment of pneumonia involves three major categories, namely, vaccines, drugs, and oxygen therapy. Oxygen therapy is often used as a supplement to other therapies when the patient faces difficulty in breathing.

Technavio's analysts forecast the global pneumonia therapeutics market to grow at a CAGR of 6.66% during the period 2017-2021 .

Covered in this report

The report covers the present scenario and the growth prospects of the global pneumonia therapeutics market for 2017-2021 . To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Pneumonia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • Pfizer

Other Prominent Vendors

  • AstraZeneca
  • Bayer
  • Biotest
  • Ono Pharmaceutical
  • Tetraphase Pharmaceuticals

Market driver

  • Increased awareness about prophylaxis by vaccines
  • For a full, detailed list, view our report

Market challenge

  • New strains of MDR bacteria
  • For a full, detailed list, view our report

Market trend

  • Strong pipeline
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: DISEASE OVERVIEW

PART 06: MARKET ECOSYSTEM

  • Market segmentation analysis

PART 07: MARKET SIZING

  • Market size and forecast 2016-2021

PART 08: PIPELINE ANALYSIS

PART 09: FIVE FORCES ANALYSIS

PART 10: MARKET SEGMENTATION BY PRODUCT TYPE

  • Segmentation by product type
  • Comparison by product type
  • Global pneumonia vaccines market
  • Global pneumonia anti-infectives market
  • Global pneumonia oxygen therapy market
  • Market opportunity by product type

PART 11: MARKET SEGMENTATION BY PNEUMONIA TYPE

  • CAP
  • HCAP

PART 12: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Pneumonia therapeutics market in Americas
  • Pneumonia therapeutics market in EMEA
  • Pneumonia therapeutics market in APAC
  • Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 15: MARKET TRENDS

  • Strong pipeline
  • Rising global initiatives for pneumonia treatment
  • Rise in respiratory infection cases

PART 16: VENDOR LANDSCAPE

PART 17: VENDOR ANALYSIS

  • Vendor overview
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • Pfizer

PART 18: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global pneumonia therapeutics categories
  • Exhibit 02: Parent market of the global pneumonia therapeutics market
  • Exhibit 03: Global pneumonia therapeutics market segments
  • Exhibit 04: Global pneumonia therapeutics market 2016-2021 ($ millions)
  • Exhibit 05: Global pneumonia therapeutics market year-over-year (YoY) growth 2017-2021 (%)
  • Exhibit 06: Global pneumonia therapeutics pipeline landscape
  • Exhibit 07: Key clinical trials in the global pneumonia therapeutics market
  • Exhibit 08: Global pneumonia therapeutics market by product type 2016-2021 (%)
  • Exhibit 09: Global pneumonia therapeutics market comparison by product type
  • Exhibit 10: Global pneumonia vaccines market 2016-2021 ($ millions)
  • Exhibit 11: Global pneumonia vaccines market YoY growth 2017-2021 (%)
  • Exhibit 12: Global pneumonia anti-infectives market 2016-2021 ($ millions)
  • Exhibit 13: Global pneumonia anti-infectives market YoY growth 2017-2021 (%)
  • Exhibit 14: Global pneumonia oxygen therapy market 2016-2021 ($ millions)
  • Exhibit 15: Global pneumonia oxygen therapy market YoY growth 2017-2021 (%)
  • Exhibit 16: Market opportunity by product type
  • Exhibit 17: Global pneumonia therapeutics market by geography 2016-2021 (%)
  • Exhibit 18: Regional comparison
  • Exhibit 19: Pneumonia therapeutics market in Americas 2016-2021 ($ millions)
  • Exhibit 20: Pneumonia therapeutics market YoY growth in Americas 2017-2021 (%)
  • Exhibit 21: Pneumonia therapeutics market in EMEA 2016-2021 ($ millions)
  • Exhibit 22: Pneumonia therapeutics market YoY growth in EMEA 2017-2021 (%)
  • Exhibit 23: Pneumonia therapeutics market in APAC 2016-2021 ($ millions)
  • Exhibit 24: Pneumonia therapeutics market YoY growth in APAC 2017-2021 (%)
  • Exhibit 25: Factors driving awareness toward prophylaxis treatment
  • Exhibit 26: Development of microbial resistance
  • Exhibit 27: Major global initiatives for pneumonia treatment
  • Exhibit 28: GlaxoSmithKline: Key highlights
  • Exhibit 29: GlaxoSmithKline: Strength assessment
  • Exhibit 30: GlaxoSmithKline: Strategy assessment
  • Exhibit 31: GlaxoSmithKline: Opportunity assessment
  • Exhibit 32: Merck Sharp & Dohme: Key highlights
  • Exhibit 33: Merck Sharp & Dohme: Strength assessment
  • Exhibit 34: Merck Sharp & Dohme: Strategy assessment
  • Exhibit 35: Merck Sharp & Dohme: Opportunity assessment
  • Exhibit 36: Novartis: Key highlights
  • Exhibit 37: Novartis: Strength assessment
  • Exhibit 38: Novartis: Strategy assessment
  • Exhibit 39: Novartis: Opportunity assessment
  • Exhibit 40: Pfizer: Key highlights
  • Exhibit 41: Pfizer: Strength assessment
  • Exhibit 42: Pfizer: Strategy assessment
  • Exhibit 43: Pfizer: Opportunity assessment